Cargando…

Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA

OBJECTIVE: Circulating tumor DNA is a promising noninvasive tool for cancer monitoring. One of the challenges in applying this tool is the detection of low-frequency mutations. The detection limit of these mutations varies between different molecular methods. The aim of this study is to characterize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fahoum, Ibrahim, Forer, Relly, Volodarsky, Dina, Vulih, Inna, Bick, Tova, Sarji, Shada, Bamberger, Zeev, Ben-Izhak, Ofer, Sabo, Edmond, Hershberg, Ruth, Hershkovitz, Dov
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090485/ https://www.ncbi.nlm.nih.gov/pubmed/30099961 http://dx.doi.org/10.1177/1533033818793653

Ejemplares similares

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas
por: Simon, Einav, et al.
Publicado: (2017)

Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection
por: Ostrow, Sheli L., et al.
Publicado: (2016)

Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy
por: Asor, Eyal, et al.
Publicado: (2017)

Hyperbaric oxygen therapy induces transcriptome changes in elderly: a prospective trial
por: Hadanny, Amir, et al.
Publicado: (2021)

Association between Nuclear Morphometry Parameters and Gleason Grade in Patients with Prostatic Cancer
por: Malshy, Kamil, et al.
Publicado: (2022)

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel
por: BAR-SELA, GIL, et al.
Publicado: (2013)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
por: Malapelle, Umberto, et al.
Publicado: (2022)

Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
por: Peleg Hasson, Shira, et al.
Publicado: (2022)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko, Brian, et al.
Publicado: (2017)

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
por: Del Re, Marzia, et al.
Publicado: (2017)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
por: Wang, Zheng, et al.
Publicado: (2021)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

P1076: PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS
por: Dann, Eldad, et al.
Publicado: (2023)

Artificial intelligence (AI) molecular analysis tool assists in rapid treatment decision in lung cancer: a case report
por: Waissengrin, Barliz, et al.
Publicado: (2023)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
por: Li, Weiting, et al.
Publicado: (2022)

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
por: Iwama, Eiji, et al.
Publicado: (2015)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR
por: Silveira, Catarina, et al.
Publicado: (2021)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
por: Sagan, Olivia A., et al.
Publicado: (2023)

Clinical Significance of Heparanase Splice Variant (T5) in Renal Cell Carcinoma: Evaluation by a Novel T5-Specific Monoclonal Antibody
por: Barash, Uri, et al.
Publicado: (2012)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
por: WANG, CHENGDE, et al.
Publicado: (2015)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
por: Filipits, Martin, et al.
Publicado: (2023)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation
por: Guha, Minakshi, et al.
Publicado: (2013)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
por: Xiang, Mingli, et al.
Publicado: (2013)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Zou, Bin, et al.
Publicado: (2017)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pfmgsfrqq4sf5l3uupq8r42d5p